# OnCo record nct00189345 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct00189345/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct00189345", "NCT00189345" ;
  schema:name "Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients"@en ;
  schema:description "A phase 2 trial of Catumaxomab in Ovarian cancer, run by AGO Study Group, completed."@en ;
  schema:url <https://onco.cc/trials/nct00189345/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00189345> ;
  onco:status "completed" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:drugs <https://onco.cc/drugs/catumaxomab/> .